Peptides derived from plasminogen activator inhibitor-1 and uses thereof
AssigneeD-Pharm Ltd.
InventorAbd Al-Roof Higazi
Life of this patent
Estimating the term…
Abstract
The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.
Claims19
An isolated peptide having the amino acid sequence as set forth in SEQ ID NO:3:
- R1-Arg-Met-Ala-Pro-Glu-Glu-Ile-Ile-Met-Asp-Arg-Pro-Phe-Leu-Phe-Val-Val-Arg R2, wherein R1 is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group;
- and R2 is selected from the group consisting of a carboxyl, amide, ester, and a carboxyl blocking group.
A pharmaceutical composition comprising an isolated peptide which has the amino acid sequence set forth in SEQ ID NO:3:
- R1-Arg-Met-Ala-Pro-Glu-Glu-Ile-Ile-Met-Asp-Arg-Pro-Phe-Leu-Phe-Val-Val-Arg R2, wherein R1 is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group;
- and R2 is selected from the group consisting of a carboxyl, amide, ester, and a carboxyl blocking group, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
A method for reducing neurological damage attributed to a stroke, traumatic brain injury, or ischemic brain injury in a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide which has the amino acid sequence set forth in SEQ ID NO:3:
- R1-Arg-Met-Ala-Pro-Glu-Glu-Ile-Ile-Met-Asp-Arg-Pro-Phe-Leu-Phe-Val-Val-Arg-R2, wherein R1 is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group;
- and R2 is selected from the group consisting of a carboxyl, amide, ester, and a carboxyl blocking group, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
A method of fibrinolytic therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a fibrinolytic agent and an isolated peptide which has the amino acid sequence as set forth in SEQ ID NO:3:
- R1-Arg-Met-Ala-Pro-Glu-Glu-Ile-Ile-Met-Asp-Arg-Pro-Phe-Leu-Phe-Val-Val-Arg-R2, wherein R1 is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group;
- and R2 is selected from the group consisting of a carboxyl, amide, ester, and a carboxyl blocking group, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.